福泰制药Vertex Pharmaceuticals Inc. (VRTX) 1998年10-K年度报告「NASDAQ」.pdf

1、 SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 10-K(Mark One)X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES-EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31,1998 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES-EXCHANGE ACT OF 1934 For

2、the transition period from _ to _ Commission file number 000-19319 VERTEX PHARMACEUTICALS INCORPORATED(Exact name of registrant as specified in its charter)MASSACHUSETTS 04-3039129 (State of incorporation)(I.R.S.Employer Identification No.)130 WAVERLY STREET CAMBRIDGE,MASSACHUSETTS 02139-4242(Addres

3、s of principal executive offices)(Zip Code)(617)577-6000 (Registrants telephone number,including area code)Securities registered pursuant to Section 12(g)of the Act:Common Stock,$0.01 par value(Title of class)Indicate by check mark whether the registrant:(1)has filed all reports required to be filed

4、 by Section 13 of 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes X No Indicate by check mark if disclosure of deli

5、nquent filers pursuant to Item 405 of Regulation S-K is not contained herein,and will not be contained,to the best of the registrants knowledge,in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K._ As of March 22,19

6、99 there were outstanding 25,400,241 shares of Common Stock,$.01 par value per share.The aggregate market value of shares of Common Stock held by non-affiliates of the registrant,based upon the last sales price for such stock on that date as reported by The Nasdaq National Stock Market,was approxima